scientific abstracts

Thursday, 13 June 2019

597

90.3% (140/155) in pSS, 92.3% (36/39) in MCTD, 93.4% (128/137) in PBC and 49.1% (28/57) in the AIH group. The positive rate of ANA in the health subjects was 11.5% (123/1073), see Figure 1. Totally, the positive rate of ANA in the AID group was 80.1% (2967/3704). The karyotypes were detected as homogeneous type (15.8% (586/3704)), nuclear particle type (49.7% (1840/3704)), cytoplasmic particle type (5.3% (196/3704)), mixed type (2.8% (91/3704)) which was mainly composed of nuclear membrane/cytoplasmic granules, more common in PBC. See Table 1. The karyotype of ANA in the health group was mainly homogenous (7.0% (75/1073)).

Figure 1 ANA positive rate in difference AID patients and healthy subjects

Conclusion: There are differences in ANA positive rates among patients with different AIDs. Some mixed karyotype analyses may provide important evidence for the diagnosis of PBC and AIH. Healthy subjects can have partial ANA positivity which is predominantly homogenous.

Disclosure of Interests: None declared


THU0611

SEVERE HIGHLY-SENSITIVE CARDIAC TROPONIN-I AND ANTI-BETA2-GLYCOPROTEIN-I IGA ANTIBODIES AT BASELINE PREDICT CORONARY PLAQUE PROGRESSION IN RHEUMATOID ARTHRITIS

George Karpouzas1, Sarah Ormseth1, Elizabeth Hernandez1, Joel Estis2, John Todd3, Matthew Budoff4, 1Harbor UCLA Medical Center, Rheumatology, West Carson, United States of America, 2Singulex, Inc., Alameda, United States of America, 3Harbor UCLA Medical Center, Cardiology, West Carson, United States of America

Background: We recently reported that serum levels of highly-sensitive cardiac troponin-I (hs-cTnI)– a specific structural myocardial biomarker–associated with occult coronary plaque presence, burden and long-term cardiovascular events in patients with rheumatoid arthritis (RA). We further demonstrated that presence of IgA antibodies against beta2-glycoprotein-1 (a-b2GPI-IgA), an apolipoprotein readily expressed in human atherosclerotic plaque associated with baseline coronary artery calcium (CAC) scores and independently predicted CAC progression in patients with RA.

Objectives: We here explored whether baseline evaluation of both hs-cTnI and a-b2GPI-IgA better predicts CAC progression than either of them in isolation.

Methods: Ninety five participants with a baseline plaque evaluation by coronary computed tomography angiography (CCTA) underwent follow-up assessment within 6±0.3 years. Coronary artery calcium (CAC) was quantified by the Agatston method. Hs-cTnI and a-b2GPI IgA Ab were assessed on the day of baseline CCTA; the latter were reconfirmed 12 weeks later, if positive. CAC change was evaluated with the MESA method as the natural logarithm plus 25 difference [(ln CAC (follow-up) + 25) – (ln CAC (baseline) + 25)]. Generalized linear models evaluated the effect of hs-cTnI, a-b2GPI-IgA and their interaction on CAC change. Models were adjusted for age, hypertension, waist-to-height ratio (obesity indicator), cumulative inflammatory burden (time-averaged C-Reactive protein), total prednisone dose and duration of statin exposure from baseline to follow-up scan.

Results: Baseline hs-cTnI was higher in a-b2GPI-IgA positive compared to negative patients [median (IQR) 1.9 [1.9-4.1] vs. 0.9 [0.7-1.4] respectively, p=0.043], hs-cTnI alone did not independently predict CAC change (β=0.214, p=0.132) in the multivariable model whereas a-b2GPI-IgA presence did (β=0.454, p=0.003). There was a significant interaction between hs-cTnI and a-b2GPI-IgA on CAC progression (Wald Chi-square=4.19, p=0.041); high hs-cTnI (>1.5pg/ml) predicted significantly greater CAC change in a-b2GPI-IgA positive patients but not in negative ones [estimated marginal mean difference (IQR)=0.36 (0.12-0.59), p=0.003 and figure 1].

Conclusion: Baseline hs-cTnI in isolation is not predictive of CAC progression in patients with RA; however, in the context of a-b2GPI-IgA presence, high hs-cTnI independently predicts significant increase in coronary atherosclerosis burden.

Disclosure of Interests: George Karpouzas Grant/research support from: Pfizer, Consultant for: Sanofi-Genzyme-Regeneron, Janssen, Roche-Gentech, Pfizer; Speakers bureau: BMS, Sanofi-Genzyme-Regeneron, Janssen, Roche-Gentech, Sarah Ormseth: None declared, Elizabeth Hernandez: None declared, Joel Estis Employee of: Singulex, John Todd Employee of: Singulex, Matthew Budoff: None declared


THU0612

KNEE JOINT PAIN IN AN ELDERLY, HEALTHY POPULATION IS ASSOCIATED WITH INFLAMMATORY ARTICULAR AND ENTHESEAL CHANGES DETECTED BY ULTRASOUND

David Simon1, Arnd Klever1, Antonella Adinolfi2, Johann Willeit3, Stefan Kiechl1, Nina Gasper1, Georg Schett1, Christian Dejacon, Annmaria Iagnocco4, Maria-Antonietta D’agostino5, Friedrich-Alexander University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany; 2University of Siena, Department of Rheumatology, Policlinico Le Scotte, Siena, Italy, 3Medical University of Innsbruck, Department of Neurology, Innsbruck, Austria, 4Department of Rheumatology, Hospital of Bruneck, Bruneck, Italy, Department of Rheumatology and Immunology, Medical University Graz, Graz, Austria, 5Università degli Studi di Torino, Dipartimento Scienze Cliniche e Biologiche, Torino, Italy, 6Hôpital Ambroise Paré, Boulogne-Billancourt, Department of Rheumatology, APHP, Paris, France

Background: Knee pain is highly prevalent in elderly and influences quality of life. Pathogenesis of knee pain in such population is commonly related to osteoarthritis (OA). It is yet unclear however, which pathological lesions in the knee contribute most to symptomatic disease.

Objectives: To define the articular and enthesal inflammatory and structural lesions that contribute to knee pain in an elderly healthy population using Power Doppler ultrasound (PDUS).

Methods: All subjects (>65 years) were part of the prospective long-term population-based Bruneck Study (1) and received a clinical and ultrasound investigation of both knees. Ultrasound was performed by an independent investigator unaware of clinical symptoms. Knee entheses (quadriceps insertion, proximal and distal patella insertion) and joint cavity were assessed. Demographic variables were recorded in all individuals. Pain sensation during knee palpation was collected and participants were asked to complete a standardized pain questionnaire for knee joints (Knee injury and osteoarthritis outcome score [KOOS], question P1-P4).

Joint changes (synovial hypertrophy, power doppler (PD) signal, joint effusion, baker cysts, osteophytes) were assessed using a GE Logic E
device. Enthesal changes such as positive PD, calcification, enthesisophytes as well as hypechoegenic area were also recorded. All ultrasound abnormalities were scored using validated OMERACT scores. The prevalence of observed changes was compared between subjects without palpatation pain and patients with pain. By summing up the articular and entheseal changes a total score was calculated and correlated with the KOOS pain values.

**Results:** A total of 303 (Male 154; Female 149) aged participants (age: 75.3±6.9 years) underwent ultrasound examination of both knees. Knee tenderness was found by 30/149 (20.1%) women and 15/154 (9.7%) men. Ultrasound effusion (p<0.010), synovial hypertrophy (p<0.001), PD synovial activity (p<0.003) and osteophytes (p<0.001) were more prevalent in women with knee tenderness than without. In men, knee tenderness was associated PD synovial activity (p<0.0014), and entheseal calcification (p<0.0003). Presence of >1 ultrasound pathology was associated with lower KOOS pain values, indicating higher impact on symptoms. This was observed in both women (r=-0.285, p=0.021) and men (r=-0.298, p=0.008).

**Conclusion:** In an elderly healthy population, knee pain is associated with the presence of joint and entheseal inflammatory lesions.

**REFERENCES:**

**Disclosure of Interests:** David Simon Grant/research support from: Novartis, Consultant for: Lilly, Speakers bureau: Janssen, Amd Klyer Grant/research support from: Lilly, Consultant for: Lilly, Speakers bureau: Abbvie, Antionella Adrioli: None declared, Stefan Kiechl: None declared, Nicola Gasperi: None declared, Georg Schett: None declared, Christian Dejaco: Speakers bureau: MSD, Pfizer, UCB, Abbvie, Roche, Novartis, Lilly, Celgene, Merck, Sandoz, Annamaria Iagnocco: None declared, Maria-Antoinetta d’Agostino: None declared

**DOI:** 10.1136/annrheumdis-2019-eular.7153

---

**THU0613 MRI AND ULTRASOUND (US) ASSESSMENT OF TEMPOROMANDIBULAR JOINT (TMJ) INVOLVEMENT IN ADULT PATIENTS WITH DIAGNOSIS OF JUVENILE IDIOPATHIC ARTHRITIS (JIA) AND NON-JIA CHRONIC INFLAMMATORY ARTHROPATHIES**

Adriano Lercara1, Gloria Crecpal1, Marco Davico2, Stefano Cricillo2, Sarah Marouen2, Enrica Vandelli3, Yves-Marie Pers3, Claudia Lomater1.

**Background:** TMJ is involved in about 50% of JIA cases, often bilateral and symmetric in up to 71% of cases1, leading to higher rate of dysfunction and anatomical abnormalities (as retrognathia, facial asymmetry, limited mouth opening, pain)2. To date MRI is the gold standard to study function and anatomical abnormalities (as retrognathia, facial asymmetry, TMJ damage on MRI but not on US; 2 TMJs had damage on US but not on MRI and 13 TMJs had damage on MRI only; the concordance was discrete (k = 0.23 (0-0.48). Only 2 TMJs had inflammation on US, of which only one was confirmed by MRI. 12 TMJs were pathological on both MRI and US; 3 TMJs were pathological on US only and 13 TMJs on MRI only; the concordance was poor (k = 0.17 (0-0.43), Se=48% (95%CI 0.28,0.68), Sp=73% (95%CI 0.47,0.99).

**Disclosure of interests:** None declared

**DOI:** 10.1136/annrheumdis-2019-eular.3069

---

**THU0614 FINGER EXTENSOR TENDON INVOLVEMENT IS FREQUENT IN EARLY RHEUMATOID ARTHRITIS**

Mihaela Maruseac1, Adrien Nzeesseu2, Maria Stoenoiu2.

**Background:** Finger extensor tendon (FET) involvement at ultrasound examination (US) was previously described in patients suffering from early and established psoriatic arthritis1. The reliability of the US measure of FET was as least as good as for synovitis2. The involvement of the FET in patients suffering from rheumatoid arthritis remains controversial. **Objectives:** To assess the involvement of FET in early rheumatoid arthritis (ERA) patients and in asymptomatic subjects (CTR).

**Methods:** Inclusion criteria for ERA patients were: less than 6 months since the ERA diagnosis; age >18 years; without DMARD treatment or oral glucocorticoid treatment. Inclusion criteria for CTR subjects were: age >18 years; no pain in hands and fingers (VAS pain =0); no known rheumatic disease such a systemic diseases, rheumatoid, psoriatic arthritises, spondyloarthritis, hand osteoarthritis, cut, chondrocalcinosis; no psoriasis, no inflammatory bowel diseases. US assessments were performed blindy to the clinical and laboratory data. FET were assessed in longitudinal and in transverse view at the metacarpophalangeal joint (MCP) and proximal phalangeal joint (PIP) level both in grey-scale (GS), power Doppler (PD) and in color Doppler (CD) mode. In addition the following joints were assessed for the presence and grade (0-3 according to OMERACT definitions) for both GS and PD synovitis: wrists, ankles, metatarsophalangeal (MTP) (2-5) and MCP (1-5) joints.

**Disclosure of interests:** None declared

**DOI:** 10.1136/annrheumdis-2019-eular.7153

---

**References:**